Venture Partner
Kevin Grove, Ph.D.
Background
Kevin Grove is a Venture Partner anchored in Seattle and has worked with Versant-funded companies across all three of the firm's Discovery Engines. Kevin brings deep disease and biology knowledge in the area of cardiometabolic conditions, along with unique drug development and commercialization experience. He also brings knowledge and understanding of the patient in the obesity and diabetes areas.
Kevin joined Versant in July 2024 and during that period worked with several new start-ups and stealth companies including Pep2Tango, Levator and Helicore, and serves on the Scientific Advisory Board of Fable Therapeutics.
History
Prior to joining Versant, Kevin spent nearly 10 years at Novo Nordisk, where he established the Obesity Research unit in Seattle. During his tenure there, Kevin worked across the target discovery, drug development and into the commercialization of drugs in the space of obesity, diabetes, NASH/MASH and CVD. Prior to joining Novo Nordisk, Kevin spent 20 years a Oregon Health Science University and was recognized as a key opinion leader in the cardiometabolic space and worked with numerous large pharma companies (notably: Genetech, Novo Nordisk, Merck, Eli Lilly and Sanofi) as well as Biotechs (notably Rhythm Px) as a consultant, collaborator and advisory board member.